This is an email from Your Coronavirus Update, a newsletter by Medium Coronavirus Blog.
At least two companies are reporting very good results from their late-stage trials. This morning Pfizer and BioNTech announced that they will be submitting their Covid-19 vaccine data to the FDA and that their full results show 95% efficacy. This comes after Moderna announced high efficacy results for its vaccine on Monday. You can read more details here.
The Covid-19 news cycle is a bit whiplash-inducing right now. The vaccine news is very hopeful (I am stoked by what I see so far) and at the same time the U.S. is in a particularly bleak point in the pandemic with rising cases, hospitalizations, and deaths. With vaccines likely on the horizon, the human loss feels unfair and preventable. Now is the time to really lean on what you know works to keep yourself and others protected from infection.
Here’s what’s new:
- New Pfizer vaccine results: Pfizer and BioNTech have finished their final clinical trial for the Covid-19 vaccine and say it is 95% effective and 94% effective in people over 65 who are at a higher risk for severe Covid-19. Read more.
- FDA authorizes first at-home Covid-19 test: The FDA has given a green light to The Lucira, which is a single use test that is intended to detect SARS-CoV-2 with a self-collected nasal swab sample in people age 14 and older who are suspected of Covid-19.
- Moderna says its vaccine is 94.5% effective: The results were analyzed by an independent data safety monitoring board, appointed by the National Institutes of Health. Read more.
Follow our Medium Coronavirus Blog for regular updates, and read some of the essential stories we’ve curated below.
Editor, Medium Coronavirus Blog
Was this email forwarded to you by a friend? Sign up to receive regular updates from our Coronavirus Team in your inbox.
New on the Blog
A few more smart reads
Immunity to the Coronavirus May Last Years, New Data Hint (New York Times)